17 results about "Prostate tumors" patented technology

This invention relates to the field of biopharmaceutical technology, and in particular to the application of myrotoxin A in the preparation of drugs for treating prostate cancer. This invention is the first to discover the function of myrotoxin A in inducing ferroptosis in DU145 prostate cancer cells by targeting and inhibiting ACSL3 protein, and its inhibitory effect on prostate cancer proliferation. Specific embodiments of this invention reveal for the first time that myrotoxin A can precisely utilize the unique metabolic vulnerability of prostate cancer cells, significantly downregulating the expression of ACSL3 protein in DU145 cells at the protein level. This, in turn, by relieving the inhibition of ferroptosis by ACSL3 protein, specifically induces ferroptosis in prostate cancer cells, ultimately effectively inhibiting tumor cell growth and achieving the therapeutic goal of targeting prostate cancer development.

The application discloses an application of an indole dione piperazine compound in preparation of a drug for resisting prostate cancer. Experiments such as MTT, flow cytometry, protein chip, molecular docking, CETSA, transmission electron microscopy and zebra fish model prove that the compound significantly inhibits proliferation of prostate tumor cells such as PC-3, 22Rv1 and DU145, blocks division of PC-3 cells in the G1 phase, and induces apoptosis and necrotic apoptosis of PC-3 cells; the mechanism is that the compound directly combines NQO1 and NRF2, activates the HO-1 / NRF2 / NQO1 pathway, promotes excessive generation of ROS, and causes NQO1-dependent oxidative stress. The zebra fish model in vivo shows that the compound inhibits growth of prostate tumors. The application provides a lead compound with a new mechanism for preventing and treating prostate cancer and potential for overcoming drug resistance.

To provide a process for preparing MDM2 inhibitors useful for treating solid tumors such as breast, colon, lung, and prostate tumors, as well as liquid tumors such as lymphomas and leukemias.SOLUTION: Provided are commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid and intermediates thereof.SELECTED DRAWING: Figure 1

The invention discloses application of 19-hydroxybufalin in preparation of a medicine for treating prostatic cancer, and belongs to the technical field of pharmaceutical preparations. The 19-hydroxybufalin is found to be targeted in vivo and in vitro for the first time, and the growth of prostate tumors is remarkably inhibited, so that the survival basis of tumor cells is fundamentally weakened, programmed death of the tumor cells is triggered, and tumor regression is effectively induced; a brand-new treatment approach is provided, namely, a non-classical drug target, namely HELLS, is degraded in a targeted manner, so that a new treatment choice is expected to be provided for a patient lacking existing target mutation; the provided 19-hydroxybufalin can be used for treating advanced prostate cancer, especially castration-resistant prostate cancer, and a new candidate treatment drug with great potential and a brand new treatment strategy are provided for effectively solving the problem that chemotherapy drug resistance and targeted therapy selection are limited in the castration-resistant prostate cancer at present.

The invention provides a machine learning analysis method and system based on prostate tumor multi-dimensional disease data and electronic equipment. The method comprises the following steps: S1, acquiring original image data, original clinical data and pathological results of prostate dominant focus tissues; s2, screening to obtain target radiomics characteristics, and establishing a radiomics model according to the target radiomics characteristics and in combination with the pathological result; establishing a deep learning model according to the original image data in combination with a pathological result; screening to obtain target clinical features, and establishing a clinical prediction model according to the target clinical features and in combination with the pathological result; s3, carrying out fusion analysis on the image omics model, the deep learning model and the clinical prediction model aiming at the prediction result of the prostate tumor multi-dimensional disease data, screening to obtain a target fusion feature, and establishing a multi-modal fusion model according to the target fusion feature in combination with a pathological result; and S4, establishing a two-dimensional column diagram based on the multi-modal fusion model.

The present application relates to a kind of compound with anti-androgen receptor activity and its use, the present application provides the compound shown in formula I, its racemate, stereoisomer, tautomer, solvate, polymorph or their pharmaceutically acceptable salt.The compound has good prostate tumor cell proliferation inhibitory activity and anti-AR activity.The compound has good in vivo metabolic properties, AUC and C max Both are higher, and the drug has good property, can be used for preventing and / or treating male hormone related disorder disease.The compound of the present application also has good hair production promoting effect, can effectively increase the number of hair follicle and the length of hair growth.

The application discloses RGD modified crocetin-paclitaxel co-loaded drug compound liposomes and a preparation method and application thereof, and belongs to the technical field of biological medicines. The RGD modified crocetin-paclitaxel co-loaded drug compound liposomes comprise RGD modified liposomes, paclitaxel and crocetin, wherein the RGD modified liposomes are used as a drug carrier to target and deliver the paclitaxel and the crocetin to prostate tumor cells, and the RGD modified liposomes are prepared by a film dispersion method or a reverse evaporation method. The prostate cancer targeted compound liposomes prepared by the application can increase the uptake of the prostate cancer cells, improve the in-vitro cytotoxicity of the prostate cancer cell line RM-1, and inhibit the growth of RM-1 ectopic solid tumors in mice, and does not cause obvious damage to other tissues.

The invention relates to the technical field of cell culture, and particularly discloses a culture device for prostate tumor cells and a using method thereof.The culture device comprises a hormone gradient generation assembly, and a dynamic control unit is installed at the top of the hormone gradient generation assembly; a plurality of groups of culture gradient diffusion assemblies are arranged between the dynamic control unit and the hormone gradient generation assembly; after the electrically-driven air supply unit is inflated and expanded, periodic pressure is applied to the cells when the silica gel pressure head passes through, mechanical stimulation is formed, the axial movement speed of the conical limiting support is set to push the culture medium to flow back and forth, and shear force is controlled; an electrically-driven air supply unit is used for controlling a compression expansion ball to inhale air so as to adjust interlayer staggered spaces on the inner sides of the interval containing grooves and controlling a culture solution injection pump set to inject hormone into diffusion gaps on the inner sides of the interval containing grooves, and then the culture solution injection pump set operates in a no-load mode to simulate air holes; and the mechanical stimulation culture of the tumor cells is completed after the circulating motion of the silica gel pressure head.

The present invention relates to an in vitro / ex vivo method for the evaluation of the aggressiveness and / or prognosis of a tumor in a subject, that comprises the evaluation of the expression of multiple genes identified in a molecular signature, whose high expression is associated with a worse prognosis for the patient, and therefore with greater tumor aggressiveness. The invention also relates to kits for determining the expression of genes belonging to the molecular signature, as well as their use for the evaluation of the aggressiveness and / or prognosis of a tumor in a subject, and to inhibitors of the expression or activity of the signature genes for use in the treatment of prostate cancer and male breast cancer.

The application discloses a kind of prostate cancer lesion detection model construction method based on contrast image feature extraction, belong to image processing field, including the following steps: establishing training sample, establishing prostate cancer lesion detection model and training prostate cancer lesion detection model;Prostate tumor detection model contains space-time feature extraction network and target detection network.In the establishment training sample, based on time intensity curve correction algorithm can automatically extract arteriolar microbubble in ultrasonic contrast video from the time segment of appearance to peak value, and prostate tumor detection becomes more sensitive.The prostate cancer lesion detection model of the application can richly extract the space-time features and prostate cancer lesions in the training samples by virtue of the advantages of three-dimensional deep learning, can adapt to different sizes of prostate cancer lesions, and makes use of the dynamic characteristics of ultrasonic contrast, and thus can improve the prediction accuracy of the lesions.

The present disclosure provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. In some embodiments, the antibodies of the disclosure bind human PSMA with high affinity and bind CD3 to induce proliferation of human T cells. The disclosure includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of tumor cells expressing PSMA. In some embodiments, the present disclosure provides bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human CD3 and a second antigen binding molecule that specifically binds human PSMA. In some embodiments, the bispecific antigen binding molecules of the present disclosure are capable of inhibiting the growth of prostate tumors expressing PSMA.The antibodies and bispecific antigen binding molecules of the disclosure are useful for the treatment of diseases and disorders where a targeted, upregulated or induced immune response is desirable and / or therapeutically advantageous. For example, the antibodies of the disclosure are useful for the treatment of various cancers.

The invention belongs to the technical field of animal model building methods, and particularly relates to a method for building a prostatic cancer animal model. Comprising the following steps: preparing prostate tumor cell suspension; preparing a male healthy BALB / c mouse; the male healthy BALB / c mice are firstly fed with the induction feed; wherein the formula of the induction feed is as follows: 1 kg of basal feed, 15 mg-25 mg of beta-cypermethrin and 50 mg-100 mg of manganese sulfate; inoculating a tumor cell suspension; and continuing to feed with the induction feed until tumor blocks are formed, and successfully constructing the prostate cancer animal model. According to the prostate cancer animal model establishing method, the process of inhibiting tumor blocks through an operation is not needed, a simpler injection method and a feeding method are combined, and the modeling success rate is increased.

The present invention relates to a lentiviral vector comprising a nucleic acid sequence encoding at least one antigen sequence selected from the group consisting of human prostatic acid phosphatase, human prostate specific antigen, human prostate-specific membrane antigen, human prostate stem cell antigen, human six-transmembrane epithelial antigen of the prostate-1 and fragments thereof. It further relates to lentiviral vector particles, isolated cells or pharmaceutical compositions comprising a lentiviral vector according to the invention. The invention further provides a combinatory treatment comprising at least one lentiviral vector, lentiviral vector particle, isolated cell or pharmaceutical composition according to the invention, and at least one anticancer agent or treatment and / or at least one immunotherapy agent or treatment. Finally, the invention provides any of the above for use in the treatment and / or prevention of prostate cancers, in particular of metastatic prostate cancers, more particularly of metastatic castration-resistant prostate cancers.

This invention discloses the application of rye ketoacid D in the preparation of ACSL3 protein inhibitors and anti-prostate cancer drugs, belonging to the field of biomedical technology. This invention is the first to discover that rye ketoacid D can effectively inhibit the protein expression level of ACSL3 in prostate cancer cells, thereby inducing and promoting ferroptosis in prostate cancer cells, and thus inhibiting the occurrence and development of prostate tumors. Therefore, rye ketoacid D can be used as an active ingredient in the preparation of ACSL3 protein inhibitors, and also exhibits excellent tumor suppression and cell killing effects in molecular targeted therapy for prostate cancer, possessing broad clinical application value.

The application discloses a kind of treatment equipment for reducing postoperative positive margin of prostate radical resection, including injection device for injecting PSMA probe into body, PET / CT imaging device, near-infrared fluorescence imaging device and surgical robot, near-infrared fluorescence imaging device shows the fluorescence level of tumor tissue and normal tissue of the prostate of the patient injected with probe, and prostate tumor tissue is fluorescently imaged according to the fluorescence intensity of probe in urine.The treatment equipment of the application carries out fluorescent imaging on tumor tissue during resection, and accurately positions, and the tumor tissue is accurately resected under the fluorescence navigation of surgical robot, and postoperative positive margin rate is significantly reduced;After prostate radical resection is carried out using the treatment equipment of the application, the risk of biochemical recurrence of patient is significantly reduced and prognosis is good;Moreover, it can also avoid the complications such as erectile dysfunction, urinary incontinence, urethral stricture caused by intraoperative damage to nerve and vascular bundle, and significantly reduce the influence on the quality of life of patient after operation.

1. The name of the design product: prostate tumor hyperthermia equipment. 2. The use of the design product: for accurate positioning of magnetic heating particles. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The present disclosure provides, among other things, methods of classifying prostate cancer, methods of analyzing a prostate tumor sample, and methods of selecting a subject for removal and dissection of lymph nodes in the pelvis (PLND). Such methods can comprise detecting an expression level for one or more genes in a panel of cell cycle progression (CCP) genes and providing a clinical cell-cycle risk (CCR) score from the expression level of the genes in the panel of CCP genes and a Cancer of the Prostate Risk Assessment (CAPRA) score.